linjc16/ctgov huggingface dataset:
Macrowire for IntracraNial Thrombectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to develop a multicenter registry of patient data and outcomes for patients undergoing intracranial thrombectomy for acute ischemic stroke secondary to emergent large vessel occlusion with delivery of reperfusion catheter over a novel macrowire (Aristotle Colossus) to perform intracranial mechanical thrombectomy.

Official Title
-----------------
MINT Registry : Macrowire for IntracraNial Thrombectomy Registry

Conditions
-----------------
Stroke, Acute Ischemic

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18-85 years Time of onset < 24 hours Acute stroke patient with NIHSS >6 CT-ASPECTS ≥ 6 Proven intracranial occlusion - (ICA-T, M1) Modified Rankin score: 0-2 Exclusion Criteria: Age <18 years or >85 years Unknown time of onset NIHSS < 5 CT ASPECTS <5 Pre-stroke morbidity, modified Rankin score > 2 Tandem occlusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants with emergent large vessel occlusion undegoing intracranial mechanical thromebctomy<br>Participants with emergent large vessel occlusion undergoing intracranial mechanical thrombectomy where the reperfusion catheter was delivered over a macrowire to perform thrombectomy. | Other: No Intervention<br>* No intervention, prospective data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to deliver reperfusion catheter to the intracranial occlusion with macrowire alone (Yes/No) |  | Intraprocedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from vascular access to first intracranial pass (minutes) |  | Procedure duration | 
| Time from vascular access to recanalization (minutes) |  | Procedure duration | 
| Vessel dissection (Yes/No) |  | Intraprocedure |
Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
As a surgical intervention, DBS can effectively relieve PD tremor, rigidity, bradykinesia and other symptoms. How to better screen patients suitable for DBS treatment and conduct reasonable preoperative and postoperative evaluation is crucial to judge the treatment effect and prognosis. The clinical symptom evaluation of PD patients can be divided into motor symptom evaluation and non-motor symptom evaluation. The motor symptoms of PD patients were evaluated by UPDRS III. The evaluation of non-motor symptoms in PD patients was mainly divided into three aspects: cognitive status, emotional status, and sleep status. Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess the cognitive status of PD patients. The Hamilton Depression Scale (HAMD) was used to assess the patients' depression status. The Hamilton Anxiety Scale (HAMA) was used to assess the patients' anxiety status. The PD Sleep Scale 2nd version, The PD Sleep Scale 2nd version, PDSS - 2), and rem Sleep Behavior Disorder Questionnaire (sweet HK) (Rapid Eye Movement Sleep behaviors Disorder Questionnaire - Hong Kong, RBDQ - HK) to assess Sleep conditions.

Official Title
-----------------
Study on Brain Network Mechanism of Deep Brain Stimulation for Parkinson's （A Retrospective Study）

Conditions
-----------------
Parkinson Disease, Deep Brain Stimulation, Non-motor Symptoms

Intervention / Treatment
-----------------
* Procedure: DBS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, age under 75, acute levodopa motor response ≥30%, and indication for STN-DBS. - Exclusion Criteria: patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery -

Ages Eligible for Study
-----------------
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| improvement and no improvement<br>We observed whether the symptoms of patients improved after DBS surgery and divided them into groups. | Procedure: DBS<br>* We observed the prognostic changes of patients after DBS surgery<br>|
| imp+ and imp-<br> | Procedure: DBS<br>* We observed the prognostic changes of patients after DBS surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| motor symptom | UPDRS III score changes | 2023.1 to 2025.12 |
Omics Techniques in Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.

Official Title
-----------------
Precision Medicine in Fatty Liver Disease: How to Identify the Patient Who Develops Steatohepatitis Using Omics Techniques

Conditions
-----------------
Non-Alcoholic Fatty Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metabolic syndrome Liver steatosis detected on transient hepatic elastography performed in the last 12 months Steatosis with or without fibrosis confirmed histologically in a liver biopsy performed in the last 12 months Exclusion Criteria: Concurrent liver disease (other than NAFLD) Chronic or prolonged use of any potential hepatotoxic drug or substance HIV infection Cancer (except basal cell carcinoma)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Steatosis<br>Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation | |
| Steatohepatitis<br>Patients with non-alcoholic fatty liver disease presenting with steatosis and degree >1 of liver fibrosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Steatosis, without fibrosis or inflammation | Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation | 12 months | 
| Steatohepatitis, with fibrosis | Patients with non-alcoholic fatty liver disease presenting with steatosis and degree >1 of liver fibrosis | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nonalcoholic fat liver disease, NASH, metabolic fat liver disease, risk factors, noninvasive markers, transcriptomics, metabolomics, proteomics, liver fibrosis
PRevalence of Obstructive Sleep apnoEa and Reduction of Promoters in AF

Study Overview
=================
Brief Summary
-----------------
This study aims to identify how many patients who have atrial fibrillation, also have sleep apnoea. This is important because sleep apnoea can be a trigger to atrial fibrillation and it can be corrected with a simple intervention. Therefore it is important to understand its prevalence (how many patients with atrial fibrillation are affected by it). Also, obesity and sleep disorders are often associated, therefore the evolution of atrial fibrillation is studied in patients who also have obesity and have lost weight compared with patients who did not loose any weight or are not obese. As medications or therapy are not changed, this is an observational study.

Official Title
-----------------
Prevalenza Delle Apnee Notturne e Riduzione Dei Fattori Promotori Nella Fibrillazione Atriale

Conditions
-----------------
Atrial Fibrillation, Osa Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Polysomnography
* Behavioral: Lifestyle counselling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria primary outcome: 1 episode of atrial fibrillation in the previous year Inclusion Criteria secondary outcome: BMI > o = 27Kg/m2 AHI >30 o con 15<AHI<30 associated with other symptoms (sleeplessness, uncontrolled hypertension and cerebral events) Exclusion Criteria: Ejection Fraction <50% HFpEF not related to atrial fibrillation. coronary artery disease valvular cardiomyopathy patient already in treatment for sleep apnoea hyperthyroidism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Polysomnography|Study of the sleep pattern|
|Behavioral: Lifestyle counselling|Weight loss counselling|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in prevalence of obstructive sleep apnoea in patients with atrial fibrillation | Change in prevalence of obstructive sleep apnoea from baseline to 3 years | Baseline and at 3, 6, 12, 24 and 36 months | 
| Percentage of men and women with obstructive sleep apnoea in patients with atrial fibrillation | Percentage of men and women with obstructive sleep apnoea in patients with atrial fibrillation | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in body weight | Change in body weight from baseline to 3 years | Baseline and at 3, 6, 12, 24 and 36 months | 
| Change in incidence of atrial fibrillation recurrencies | Change in incidence of atrial fibrillation recurrencies from baseline to 3 years | Baseline and at 3, 6, 12, 24 and 36 months | 
| Change in quality of life | Change in quality of life from baseline to 3 years | Baseline and at 3, 6, 12, 24 and 36 months |
Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
Pancreatic cancer (PCA) is a leading death-related cancer. There is an urgent need for accurate, noninvasive diagnostic options in the early detection of pancreatic cancer (PCA), since delayed diagnosis increases the risk of metastasis and recurrence. In this study, by analyzing gut and fecal microbial data among the pancreatic versus healthy populations, we aim to establish an early detection tool to improve PCA detection, and to explore potential diagnostic biomarkers.

Official Title
-----------------
SCREENING ORAL AND GUT MICROBES AS A MORE ACCURATE NON-INVASIVE TOOL FOR PANCREATIC CANCER EARLY DETECTION: A POPULATION-BASED CASE-CONTROL STUDY IN CHINA

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Other: Oral and Fecal Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCA Newly diagnosed pancreatic cancer patients; No symptoms of jaundice; Did not yet receive any treatment NC Individuals who were undergoing routine screenings or physical examination Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PCA<br>pancreatic cancer patients | Other: Oral and Fecal Sample Collection<br>* No interventions<br>|
| NC<br>normal control | Other: Oral and Fecal Sample Collection<br>* No interventions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microbial features by 16s rRNA sequencing |  | within 180 days |
Pulse-Width Modulation

Study Overview
=================
Brief Summary
-----------------
The overarching aim of this project is to modulate the pulse-width during stimulation of pedicle screws and record the response thresholds associated with each PWM setting. During this initial phase of the investigation, no further data will be collected.

Detailed Description
-----------------
In vivo electrical stimulation of pedicle screws is a well-documented modality for evaluating potential breach of the pedicle wall. However, previous research has focused primarily on the stimulation threshold intensity required to elicit a neurophysiological response. Other stimulation parameters, such as pulse-width, remain uninvestigated. The goal is to obtain data on the pulse-width vs. CMAP relationship.

Official Title
-----------------
Pulse-width Modulation During Pedicle Screw Stimulation

Conditions
-----------------
Spinal Fusion, Spinal Stenosis

Intervention / Treatment
-----------------
* Diagnostic Test: Pulse width modulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A patient will be eligible for study participation once they have been booked for a surgery involving pedicle screw placement and intraoperative neuromonitoring. Exclusion Criteria: The study excludes neonates, minors, pregnant women, prisoners and cognitively impaired patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pedicle Screw Stimulation Arm<br> | Diagnostic Test: Pulse width modulation<br>* Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CMAP response under three different pulse-width settings | Upon completion of the pedicle screw placements, each screw will be stimulated utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds. The stimulation intensity required to elicit a compound muscle action potential (CMAP) will be recorded for each pulse-width parameter. This is measured in microvolts (uV). | Within operating room upon completion of pedicle screw placement. 1 day |
Intestinal Biomarker Analysis After ECP for ICI Colitis

Study Overview
=================
Brief Summary
-----------------
It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the chnages of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.

Detailed Description
-----------------
It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the changes of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.

Official Title
-----------------
Intestinal Biomarker Analysis After ECP for ICI Colitis

Conditions
-----------------
Colitis, Immune Checkpoint Inhibitor-Related Colitis

Intervention / Treatment
-----------------
* Other: Intestinal tissue analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICI colitis Exclusion Criteria: no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Intestinal tissue analysis|Intestinal tissue analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T cell number and phenotype measurement in the intestinal tract | Analysis of CD3+ T cells by flow cytometry | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T cell number measurement by immunohistochemistry | Analysis of CD3+ T cells by immunohistochemistry | 6 months | 
| Analysis of arginase amounts in the intestinal tract using qPCR | Analysis of arginase mRNA expression by realtime PCR (qRT-PCR) | 6 months |
The Impact of the COVID-19 Pandemic on the Patient in Need of an Intervention

Study Overview
=================
Brief Summary
-----------------
Mixed-method observational study: the impact of pandemic related changes in healthcare on quality of life and experiences with healthcare in Dutch patients undergoing surgery or another intervention during the covid pandemic (2020-2021). Phase 1: qualitative study to gain insight in relevant themes in Patient Reported Experiences Measures (PREMs) by conducting focus groups Phase 2: creating and validating a questionnaire based on themes identified in phase 1 Phase 3: questionnaire study among Dutch patients who underwent an intervention in 2020-2021 using the validated questionnaire of phase 2. The answers will be linked to data from national patients registries in surgery, cardiology, orthopedics and neurology.

Official Title
-----------------
The Impact of the COVID-19 Pandemic on the Patient in Need of an Intervention - COVID Surg III

Conditions
-----------------
Surgical Procedures, Operative, COVID-19, SARS-CoV-2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing surgery or intervention in the Netherlands in 2020 or 2021 Exclusion Criteria: participation language restricted to Dutch
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Reported Experience Measures | [will be specified based on phase 1 of the study, see description] | 2020-2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Specialties, Surgical, Surgery Department, Hospital
Lung Ultrasound - Prospective Study

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to determine whether lung ultrasound can predict extubation success in neonates with respiratory distress. Participants will undergo a lung ultrasound pre- and post-extubation.

Official Title
-----------------
The Utility of Lung Ultrasound Scores to Determine Extubation Readiness in Neonates With Respiratory Distress on Mechanical Ventilation

Conditions
-----------------
Respiratory Distress of Newborn

Intervention / Treatment
-----------------
* Device: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants born at UnityPoint Health Meriter Hospital and University of Minnesota admitted to the Neonatal Intensive Care Unit (NICU) with respiratory distress requiring intubation Meeting the extubation readiness criteria per the attending neonatologist Exclusion Criteria: Known major congenital disease (chromosomal abnormality, heart disease, respiratory malformation) Neonates with parents that are less than 18 years old

Ages Eligible for Study
-----------------
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lung ultrasound<br>Participants undergo pre- and post-extubation lung ultrasound | Device: Ultrasound<br>* Ultrasound of lungs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability of lung ultrasound score to predict extubation success | Correlate the lung ultrasound score to the success of extubation, which is defined as remaining extubated for >72 hours. Ultrasound scores are measured on a 4-point scale (0=normal,3 = most abnormal). | 12 hours pre-extubation to 24 hours post extubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pre- and post-extubation lung ultrasound scores | Ultrasound scores are measured on a 4-point scale (0=normal,3 = most abnormal). | 12 hours pre-extubation to 24 hours post extubation | 
| Time to re-intubation | Length of time from extubation to re-intubation. | Up to 72 hours post-intubation | 
| Change in heart rate | Measure of heart rate before and after ultrasound procedure | 5 minutes before to 5 minutes after lung ultrasound | 
| Change in respiratory rate | Measure of respiratory rate before and after ultrasound procedure | 5 minutes before to 5 minutes after lung ultrasound | 
| Change in oxygen saturation | Measure of oxygen saturation before and after ultrasound procedure | 5 minutes before to 5 minutes after lung ultrasound |